Showing 1861-1870 of 5643 results for "".
- Harrow Enters Into Agreement to Acquire Exclusive US Rights to Five Ophthalmic Products from Novartishttps://modernod.com/news/harrow-enters-into-agreement-to-acquire-exclusive-us-rights-to-five-ophthalmic-products-from-novartis/2481292/Harrow announced it has entered into a agreement for the acquisition of the exclusive US commercial rights to five FDA‑approved ophthalmic products from Novartis in a deal worth up to $175 million. This transaction, which is the second acquisition transaction between Har
- Eversight and the Department of Health–Abu Dhabi Partner to Establish UAE’s First Eye and Tissue Bankhttps://modernod.com/news/eversight-and-the-department-of-health-abu-dhabi-partner-to-establish-uaes-first-eye-and-tissue-bank/2481291/Global nonprofit eye bank Eversight and the Department of Health – Abu Dhabi (DoH) are partnering to establish the first eye and tissue bank in the United Arab Emirates (UAE). The
- Re-Vana Therapeutics Raises $11.9 Million to Advance Drug Delivery Productshttps://modernod.com/news/re-vana-therapeutics-raises-119-million-to-advance-drug-delivery-products/2481266/Re-Vana Therapeutics announced the closure of its Series A round with $11.9 million in funding, an oversubscription of $4 million. The proceeds will advance the development of Re-Vana's novel and proprietary photo-crosslinked EyeLief, EyeLief-SD, and OcuLief 
- FDA Grants Breakthrough Therapy Designation for Iveric Bio's Avacincaptad Pegol for Geographic Atrophyhttps://modernod.com/news/fda-grants-breakthrough-therapy-designation-for-iveric-bios-avacincaptad-pegol-for-geographic-atrophy/2481251/Iveric bio announced that the FDA has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). To date, A
- Nidek Launches the NT-1p Non-Contact Tono/Pachymeterhttps://modernod.com/news/nidek-launches-the-nt-1p-non-contact-tonopachymeter/2481241/Nidek announced the launch of the NT-1p Non-Contact Tono/Pachymeter. The NT-1p is an innovative device that fully automates reliable non-contact tonometry and pachymetry. By placing the chin on the chinrest, the NT-1p automatically detects the position of the eyes and begins measurement without p
- Nicox Outlines Future Development and Partnering Plans for NCX 470https://modernod.com/news/nicox-outlines-future-development-and-partnering-plans-for-ncx-470-in-glaucoma/2481228/Nicox SA announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in phase 3 development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. “Our market research&nbs
- Medicontur Launches Bi-Flex Elon Nondiffractive EDOF IOLhttps://modernod.com/news/medicontur-launches-bi-flex-elon-nondiffractive-edof-iol/2481224/Medicontur announced the launch of the Bi-Flex Elon Nondiffractive EDOF IOL. The Elon, which was launched on September 6, features proprietary Wavefront Linking technology that is designed to create a true elongated focus with minimal optical disturbances. This non-d
- CooperVision Adds SynergEyes to Expand Specialty Contact Lens Adoption in North Americahttps://modernod.com/news/coopervision-adds-synergeyes-to-expand-specialty-contact-lens-adoption-in-north-america/2481220/Deepening its commitment to expand specialty contact lens adoption in North America and worldwide, CooperVision has added
- Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol for the Treatment of Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-fda-acceptance-of-the-new-drug-application-for-cyclasol-for-the-treatment-of-dry-eye-disease/2481186/Novaliq announced that the FDA has accepted the new drug application (NDA) for CyclASol (cyclosporine ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment for the signs and symptoms of dry eye disease (DED). The agency completed the filing revi
- Harrow Sells Non-Ophthalmic Compounding Businesshttps://modernod.com/news/harrow-sells-non-ophthalmic-compounding-business/2481162/Harrow announced the sale of its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation. Financial terms of the deal were not disclosed. Revelation purchased the assets of Harrow’s non‑ophthalmic c